Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBT: 2020-2024

Historic EBT for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to -$70.1 million.

  • Monte Rosa Therapeutics' EBT fell 27.20% to -$30.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year increase of 118.45%. This contributed to the annual value of -$70.1 million for FY2024, which is 48.06% up from last year.
  • Monte Rosa Therapeutics' EBT amounted to -$70.1 million in FY2024, which was up 48.06% from -$135.0 million recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year EBT high stood at -$25.8 million for FY2020, and its period low was -$135.0 million during FY2023.
  • Its 3-year average for EBT is -$104.5 million, with a median of -$108.5 million in 2022.
  • In the last 5 years, Monte Rosa Therapeutics' EBT crashed by 148.62% in 2021 and then surged by 48.06% in 2024.
  • Yearly analysis of 5 years shows Monte Rosa Therapeutics' EBT stood at -$25.8 million in 2020, then slumped by 148.62% to -$64.1 million in 2021, then tumbled by 69.34% to -$108.5 million in 2022, then fell by 24.44% to -$135.0 million in 2023, then soared by 48.06% to -$70.1 million in 2024.